Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Mike Dymond"'
Autor:
Mark E. Robson, Seock-Ah Im, Elzbieta Senkus, Binghe Xu, Susan M. Domchek, Norikazu Masuda, Suzette Delaloge, Nadine Tung, Anne Armstrong, Mike Dymond, Anitra Fielding, Allison Allen, Pierfranco Conte
Publikováno v:
European Journal of Cancer. 184:39-47
Autor:
Judith Balmaña, Mike Dymond, Elizabeth S. Lowe, Natalia Lukashchuk, Maria Winter, Nadine Tung
Publikováno v:
Cancer Research. 83:OT2-18
Background: In early breast cancer (BC), neoadjuvant therapy can promote de-escalation of surgery or treat micrometastases. Pathological complete response (pCR) is a standard primary endpoint in neoadjuvant BC studies, and correlates with long-term o
Autor:
Jung-Min Lee, Richard G. Moore, Sharad Ghamande, Min S. Park, John P. Diaz, Julia Chapman, James Kendrick, Brian M. Slomovitz, Krishnansu S. Tewari, Elizabeth S. Lowe, Tsveta Milenkova, Sanjeev Kumar, Mike Dymond, Jessica Brown, Joyce F. Liu
Publikováno v:
Clinical Cancer Research. 28:4186-4193
Purpose: The efficacy, safety, and tolerability of cediranib plus olaparib (cedi/ola) were investigated in patients with nongermline–BRCA-mutated (non-gBRCAm) platinum-resistant recurrent ovarian cancer. Patients and Methods: PARP inhibitor–naïv
Autor:
Joyce F. Liu, Jessica Brown, Mike Dymond, Sanjeev Kumar, Tsveta Milenkova, Elizabeth S. Lowe, Krishnansu S. Tewari, Brian M. Slomovitz, James Kendrick, Julia Chapman, John P. Diaz, Min S. Park, Sharad Ghamande, Richard G. Moore, Jung-Min Lee
Purpose:The efficacy, safety, and tolerability of cediranib plus olaparib (cedi/ola) were investigated in patients with nongermline–BRCA-mutated (non-gBRCAm) platinum-resistant recurrent ovarian cancer.Patients and Methods:PARP inhibitor–naïve w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2b1a7c664e9daea0276d5c5ea1999fc3
https://doi.org/10.1158/1078-0432.c.6531047.v1
https://doi.org/10.1158/1078-0432.c.6531047.v1
Autor:
Joyce F. Liu, Jessica Brown, Mike Dymond, Sanjeev Kumar, Tsveta Milenkova, Elizabeth S. Lowe, Krishnansu S. Tewari, Brian M. Slomovitz, James Kendrick, Julia Chapman, John P. Diaz, Min S. Park, Sharad Ghamande, Richard G. Moore, Jung-Min Lee
Supplementary Figure from Cediranib in Combination with Olaparib in Patients without a Germline BRCA1/2 Mutation and with Recurrent Platinum-Resistant Ovarian Cancer: Phase IIb CONCERTO Trial
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d8d0f9527cf6422f35243a509173c57b
https://doi.org/10.1158/1078-0432.22482983
https://doi.org/10.1158/1078-0432.22482983
Autor:
Joyce F. Liu, Jessica Brown, Mike Dymond, Sanjeev Kumar, Tsveta Milenkova, Elizabeth S. Lowe, Krishnansu S. Tewari, Brian M. Slomovitz, James Kendrick, Julia Chapman, John P. Diaz, Min S. Park, Sharad Ghamande, Richard G. Moore, Jung-Min Lee
Supplementary Table from Cediranib in Combination with Olaparib in Patients without a Germline BRCA1/2 Mutation and with Recurrent Platinum-Resistant Ovarian Cancer: Phase IIb CONCERTO Trial
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::51ed6f41af0a302c9eca2d666b755e1d
https://doi.org/10.1158/1078-0432.22482977.v1
https://doi.org/10.1158/1078-0432.22482977.v1
Publikováno v:
Lab Animal. 46:207-211
Autor:
Iwanka Kozarewa, Min S. Park, Sharad A. Ghamande, Jung-Min Lee, Brian M. Slomovitz, Elizabeth S. Lowe, John P. Diaz, James E. Kendrick, Richard G. Moore, Krishnansu S. Tewari, Mike Dymond, Sanjeev Kumar, Joyce F. Liu, Tsveta Milenkova, Julia Chapman
Publikováno v:
Journal of Clinical Oncology. 38:6056-6056
6056 Background: A Phase I trial (NCT01116648) of cediranib (cedi) in combination with olaparib (ola) (cedi + ola) demonstrated an overall response rate of 44% in patients (pts) with recurrent ovarian cancer (OC), including pts without a deleterious
Autor:
Hui Zhang, Ian Robinson, David J. Keeling, Mike Dymond, Mark Biffen, Stephen Delaney, John Bell
Publikováno v:
Toxicology and applied pharmacology. 338
AZD8848 is a TLR7 agonist antedrug developed for administration by inhalation dosing for the treatment of allergic diseases, such as asthma. Allergic asthma is associated with increased levels of Th2 cytokines which are suppressed for extended period
Autor:
Sally A. Price, Rob Riley, Mike Dymond, Alison Holt, Rosanna Marsella, Ian Peers, Jaimini Reens, Malbinder Fagura, Clare Murray, Matt Devalaraja, Adam Hargreaves, Kim Ahrens
Publikováno v:
The Journal of investigative dermatology. 136(3)
Atopic dermatitis (AD) is an inflammatory skin disease characterized by infiltration of skin homing lymphocytes into the dermis. Most of these lymphocytes express the chemokine receptor CCR4, and the frequency of blood CCR4(+) lymphocytes correlates